Lastly, considering the genetic diversity among ovarian cancer patients, efforts should also be focused on establishing predictive biomarkers that can identify individuals who would benefit the most from GPCR-targeted treatments, thereby advancing the personalised medicine approach in oncology. Here, LPAR3 is linked to ovarian carcinoma.